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Abstract
Background : Becker-Kiener muscular dystrophy (BMD) represents an X-linked genetic disease associated with
myocardial involvement potentially resulting in dilated cardiomyopathy (DCM). Early diagnosis of cardiac
involvement may permit earlier institution of heart failure treatment and extend life span in these patients. Both
echocardiography and nuclear imaging methods are capable of detecting later stages of cardiac involvement
characterised by wall motion abnormalities. Cardiovascular magnetic resonance (CMR) has the potential to detect
cardiac involvement by depicting early scar formation that may appear before onset of wall motion abnormalities.
Methods : In a prospective two-center-study, 15 male patients with BMD (median age 37 years; range 11 years
to 56 years) underwent comprehensive neurological and cardiac evaluations including physical examination,
echocardiography and CMR. A 16-segment model was applied for evaluation of regional wall motion abnormalities
(rWMA). The CMR study included late gadolinium enhancement (LGE) imaging with quantification of myocardial
damage.
Results : Abnormal echocardiographic results were found in eight of 15 (53.3%) patients with all of them
demonstrating reduced left ventricular ejection fraction (LVEF) and rWMA. CMR revealed abnormal findings in
12 of 15 (80.0%) patients (p = 0.04) with 10 (66.6%) having reduced LVEF (p = 0.16) and 9 (64.3%) demonstrating
rWMA (p = 0.38). Myocardial damage as assessed by LGE-imaging was detected in 11 of 15 (73.3%) patients with
a median myocardial damage extent of 13.0% (range 0 to 38.0%), an age-related increase and a typical
subepicardial distribution pattern in the inferolateral wall. Ten patients (66.7%) were in need of medical heart
failure therapy based on CMR results. However, only 4 patients (26.7%) were already taking medication based on
clinical criteria (p = 0.009).
Conclusion : Cardiac involvement in patients with BMD is underdiagnosed by echocardiographic methods
resulting in undertreatment of heart failure. The degree and severity of cardiac involvement in this population is
best characterised when state-of-the-art CMR methods are applied. Further studies need to demonstrate
whether earlier diagnosis and institution of heart failure therapy will extend the life span of these patients.
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Background
Muscular dystrophy type Becker-Kiener (BMD) and type
Duchenne (DMD) represent X-linked genetic diseases
related to mutations in the dystrophin gene which is
located on chromosome Xp21.1 [1]. BMD has been
described to have a prevalence rate of 2.4 per 100,000 and
is less common than DMD [2]. While the protein dys-
trophin is totally absent or dysfunctional in DMD, BMD
is characterised by a reduced expression of (possibly dys-
functional) dystrophin. Respiratory failure constitutes the
main cause of mortality (mostly until the third decade of
life) in DMD, whereas BMD patients demonstrate a later
onset and a different as well as slower progression of the
disease: BMD patients may survive until the sixth decade
of life and cardiomyopathy represents the number one
cause of death [3].
Myocardial involvement with the development of dilated
cardiomyopathy (DCM) has been described in up to 72%
of BMD patients, mainly based on echocardiographic
studies [4]. It is believed that dystrophin protein dysfunc-
tion, fragility or absence is causing defects in plasma
membrane stabilization, in signal and force transduction
and in resistance to mechanical stress. Additional
mechanical stress may then lead to further disruption of
the plasma membrane-sarcomere interaction resulting in
cardiomyopathy. DCM is progressive and associated with
heart failure, ventricular arrhythmias and is an important
cause of morbidity and mortality in these patients [5].
Early diagnosis of cardiac involvement in patients with
BMD may be useful, since an early institution of heart fail-
ure medication may lead to beneficial ventricular remod-
elling with improvement in LV systolic function or at least
to decelerating progressive dysfunction [6,7]. However,
early diagnosis may be difficult using conventional non-
invasive methods such as echocardiography as primarily
wall motion abnormalities are depicted which character-
ise the later stages of myocardial involvement. Therefore,
cardiovascular magnetic resonance (CMR) may be a
promising non-invasive tool for accurate and comprehen-
sive cardiac evaluation of patients with muscular dystro-
phy (MD) – and in particular BMD – enabling a more
timely implementation of appropriate treatment strate-
gies [8-11]. However, no comprehensive and targeted
CMR studies have been performed so far on patients with
BMD.
With this study, we aimed at 1) comprehensively charac-
terising cardiac disease manifestation in patients with
BMD, 2) demonstrating the superiority of CMR compared
to conventional echocardiography in cardiac evaluation
of patients with BMD and 3) elucidating the in vivo car-
diac damage pattern of patients with BMD.
Methods
Study design
In a prospective two-center-study, 15 patients with BMD
were consecutively ascertained and studied with respect to
their neurological disorder at the neuromuscular outpa-
tient clinic of the Department of Neurology, University of
Ulm, Germany, followed by a comprehensive cardiologi-
cal work-up at the Division of Cardiology of the Robert-
Bosch-Krankenhaus Stuttgart, Germany. The diagnosis of
BMD was confirmed by skeletal muscle biopsy evaluation
with immunohistochemical analysis of the dystrophin
protein and/or a genetic work-up with screening for dys-
trophin gene deletion and duplication. Cardiological
work-up included physical examination, 12-lead ECG,
echocardiography and CMR. Blood samples were
obtained for laboratory studies including measurement of
total creatine kinase (CK), cardiac troponin-I (TnI), brain-
natriuretic-peptide (BNP) and C-reactive-protein (CRP)
apart from others. This study was approved by the local
ethical committee. Written informed consent was
obtained from each patient or his legal guardian before
inclusion to this study.
Echocardiography
Two-dimensional echocardiography was performed on a
commercially available system (Vivid 7, GE Healthcare)
using a 3.5-MHz transducer with the patient in the left lat-
eral decubitus position. Standard two-dimensional long
and short axis views were recorded with the transducer in
the apical and parasternal position. Measurements
included left ventricular (LV) endsystolic and enddiastolic
volumes. Biplane LV ejection fraction (LVEF) was calcu-
lated using the Simpson's rule. A semiquantitative global
wall motion score index (GWMS) was calculated based on
a 16-segment model as recommended by the American
Society of Echocardiography [12]: two experienced
echocardiographers blinded to the patient's clinical infor-
mation visually scored wall motion on a 0 to 3 scale for
each wall segment (normal = 0, hypokinetic = 1, akinetic
= 2, dyskinetic = 3). The GMWS was then calculated as the
sum of the myocardial wall motion segment scores
divided by the number of segments assessed.
Cardiovascular magnetic resonance
Electrocardiographic-gated CMR was performed in
breath-hold using a 1.5-T system (Magnetom Sonata, Sie-
mens Medical Solutions, Erlangen, Germany). Both cine
and late gadolinium enhancement (LGE) short-axis CMR
images were prescribed every 10 mm (slice thickness 6
mm) from base to apex. In-plane resolution was typically
1.2 × 1.8 mm. In addition to cine CMR, LGE images were
acquired on average five to ten minutes after contrast
administration with the use of a segmented inversion
recovery gradient echo technique with constant adjust-
ment of inversion time [13]. The contrast dose (Magnev-Journal of Cardiovascular Magnetic Resonance 2008, 10:50 http://www.jcmr-online.com/content/10/1/50
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ist®, Bayer-Schering, Germany) was 0.15 mmol/kg. In
addition, fat-saturated and T2-weighted images were
obtained to allow differentiation among subepicardial
LGE, epicardial fat, and pericardial effusion.
Cine and contrast images were evaluated by two blinded
observers as described elsewhere [14]. In brief, endocar-
dial and epicardial borders were outlined on the short-
axis cine images. Volumes and EF were derived by summa-
tion of epicardial and endocardial contours. The extent of
LGE was planimetered applying ImageJ software
(National Institutes of Health, Bethesda, Md, USA) on the
short-axis contrast images with the use of an image inten-
sity level ≥4 SD above the mean of remote myocardium to
define LGE indicative of myocardial damage. In addition,
a semiquantitative GWMS was calculated based on a 16-
segment model with cine short-axis CMR images similar
to echocardiographic analysis.
Statistical analysis
Data for continuous variables are expressed as median val-
ues in addition to minimal and maximal values, whereas
data for categorical variables are expressed as the number
and the percentage of patients. Comparisons between
groups were done using a two-sided unpaired Student's t-
test for normally distributed, and Mann-Whitney U test
for non-normally distributed continuous variables. For
categorical variables we used the chi-square test and
Fisher's exact test, where appropriate. Agreement between
methods was measured with Kappa statistics. Simple lin-
ear regression analyses were performed in order to iden-
tify possible determinants of reduced LVEF. The difference
between two groups was defined to be statistically signifi-
cant if the two-sided p-value was < 0.05.
Results
Patient characteristics
The patient characteristics are shown in Table 1. The
median age of this collective was 37 years with a maxi-
mum of 56 years and a minimum of 11 years. Muscle
biopsy had been performed in 13 patients with 12 of
them demonstrating reduced levels of dystrophin in the
immunohistochemical stainings. Genetic analyses for
dystrophin gene deletion and duplication mutations were
available in 12 patients with eight of them demonstrating
DNA mutations. Cardiac involvement indicating early or
advanced DCM had been previously diagnosed in seven
patients by echocardiography.
Laboratory and ECG findings
As expected, all patients had elevated serum CK enzymes,
however, all but one patient were TnI-negative suggesting
a skeletal muscle origin of these enzymes (Table 2). Inter-
estingly, BNP serum values were elevated only in two
patients in spite of depressed LV function (LVEF <60%) in
10 patients as demonstrated by CMR analyses. ECG
abnormalities were observed in seven patients (Table 2).
However, only four of these seven patients demonstrated
those ECG abnormalities previously described to be typi-
cal in patients with MD [15] including a R:S-ratio ≥1.0 in
lead V1, a deep Q-wave in leads I, II, aVL, V5-V6 or a com-
plete right bundle branch block (Fig. 1).
Table 1: Patient characteristics
Patient no. Age
[years]
BMI
[kg/m2]
Age at 
BMD 
diagnosis
[years]
Family 
history for 
BMD
Skeletal 
muscle 
biopsy
Genetic 
study
Myopathic 
EMG
Established 
heart 
disease
Current 
medication
1 49 31 45 - + + + + ACE-I + β-
BA + Diur.
2 56 29 25 - + n/a + + β-BA + Diur.
3 42 22 15 - + - + + ACE-I + 
Diur.
4 51 23 1 - + - + + -
5 26 22 4 - + - + - -
6 23 24 1 - + + + + -
7 37 24 6 - + - + - -
8 35 23 10 - + + + + ACE-I
9 26 19 6 - + n/a + - -
10 43 23 20 - - + + - -
11 11 23 2 - + n/a + - -
12 41 25 1 + + + + - -
13 14 19 0.5 - + + + - -
14 12 14 6 - n/a + + - -
15 55 23 33 + + + + + -
BMI = body mass index; EMG = electromyogram; ACE-I = angiotensin-converting-enzyme inhibitor; β-BA = beta-blocking agent; Diur. = diuretic; n/
a = not applied.Journal of Cardiovascular Magnetic Resonance 2008, 10:50 http://www.jcmr-online.com/content/10/1/50
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Echocardiographic results in comparison to CMR results
Abnormal echocardiographic results defined as
LVEF<60% and/or visual observation of rWMA were
present in eight of 15 (53.3%) patients with all eight
patients demonstrating reduced LVEF as well as some
rWMA (median GWMS = 0.19; range 0 to 1.19). Interest-
ingly, CMR revealed abnormal findings (defined as
LVEF<60% and/or rWMA and/or presence of LGE) in 12
of 15 (80.0%) patients (p = 0.040 compared to echocardi-
ography) with 10 (66.6%) of them having reduced LVEF
(median LVEF = 52%; range 27% to 70%; p = 0.16 com-
pared to echocardiography) as well as 9 (64.3%) demon-
strating rWMA (median GWMS = 0.19; range 0 to 1.06; p
= 0.38 compared to echocardiography). Both techniques
revealed rWMA in the same eight patients. However, using
echocardiography rWMA was mostly observed in septal
wall segments (n = 4) followed by lateral segments (n = 2)
while CMR revealed rWMA primarily in the (infero-)lat-
eral segments (n = 6). The kappa-test showed good agree-
ment in the assessment of rWMA with echocardiography
compared to CMR when studies without any rWMA were
included to the analysis (kappa = 0.86). However, there
was only a modest agreement in the assessment of rWMA
when studies without rWMA were excluded (kappa =
0.37).
Myocardial damage imaged with CMR
Myocardial damage as indicated by LGE imaging was
detected in 11 of 15 (73.3%) patients with a median myo-
cardial damage extent of 13.0% (range 0 to 38.0%; Fig. 2).
The most common pattern of LGE was a subepicardial to
intramural extension in the inferolateral wall (n = 8) fol-
lowed by an intramural location in septal segments (n =
2) and a transmural pattern in the lateral wall in one
patient. A substantial agreement between the presence of
myocardial damage as demonstrated by LGE imaging and
rWMA was detected by kappa analysis (kappa = 0.69).
Interestingly, two patients with preserved systolic LV func-
tion also demonstrated subepicardial LGE in the inferola-
teral wall. Correlation and regression analyses revealed a
substantial association between increasing myocardial
damage extent measured by LGE imaging and higher age
(r2 = 0.770; p < 0.001). The youngest patient demonstrat-
ing at least some LGE was found to be 26 years of age and
all patients older than 26 years had some myocardial
damage. LV systolic function was depressed in the absence
of LGE only in one patient aged 23 years.
Comparison of patients with normal vs. reduced LVEF
When patients with normal LVEF (≥60%; n = 5) were
compared to those with reduced LVEF (<60%; n = 10), sig-
nificant differences were detected for age, BMI, LV-EDV,
LV-mass, LVEDD, GWMS and LGE extent (Table 3). Right
ventricular systolic function tended to be also reduced in
those patients with depressed LV function, however, this
difference did not reach statistical significance. In order to
find out determinants of reduced LVEF (as measured by
CMR) we performed simple linear regression analysis
(Table 4 and Fig. 3): There was a significant decline of
LVEF with increasing myocardial damage extent (as meas-
ured by LGE imaging). Decreased LVEF was also associ-
ated with increasing LV-EDV, LV mass and LVEDD. As
expected, the highest coefficient of determination of LVEF
was calculated for the parameter GWMS confirming that
reduction in LVEF is due to the extent and severity of
rWMA. Furthermore, higher age was associated with a
Table 2: Patient findings
Patient no. Age
[years]
CK
[U/L]
TnI
[μg/L]
CRP >0.5 mg/dL BNP >80 pg/mL Abnormal ECG 
signs
Abnormal Echo 
findings
Abnormal CMR 
findings
1 49 3609 0.66 No No Yes Yes Yes
2 56 593 0.01 No Yes Yes Yes Yes
3 42 2181 0.01 No No No Yes Yes
4 51 311 0.01 No No Yes Yes Yes
5 26 2570 0.02 No No No No Yes
6 2 3 3 1 0 0 . 0 2 N oN oN oN oY e s
7 37 564 0.01 No No Yes Yes Yes
8 3 5 8 2 8 0 . 0 1 N oN oN oY e sY e s
9 26 3668 0.01 No No No No Yes
10 4 3 6 1 1 0 . 0 1 N oN oN oN oY e s
11 11 2845 0.01 No No No No No
12 41 315 0.01 No No Yes Yes Yes
13 14 28194 0.01 No No No No No
14 12 6875 0.03 No No Yes No No
15 55 1532 0.01 Yes Yes Yes Yes Yes
CK = creatinine kinase; TnI = troponin I; CRP = C-reactive protein; BNP = brain-natriuretic protein; ECG = electrocardiogram.Journal of Cardiovascular Magnetic Resonance 2008, 10:50 http://www.jcmr-online.com/content/10/1/50
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decrease in systolic LV function. A meaningful multivari-
ate regression analysis could not be performed due to the
limited size of this cohort.
Necessity of medical heart failure therapy
Clinical examination revealed skeletal muscle involve-
ment in 12 patients (80.0%), however, at least minor
degrees of skeletal muscle weakness and pathology were
detected by EMG in all patients limiting their effort and
exercise capacity, thereby potentially masking cardiac
exercise-dependent symptoms. Only four patients
(26.7%) were already taking heart failure medication
(Table 1) although cardiac involvement including early or
advanced DCM had been previously diagnosed in seven
patients (46.7%). CMR examination revealed cardiac
involvement in five more patients increasing the number
of patients with abnormal left ventricles to 12 (80.0%; p
= 0.019) with 10 of them (66.7%) having reduced LV
systolic function. Therefore, these patients were regarded
as in need for medical therapy (p = 0.009 compared to
those patients already on therapy) considering the recom-
mendations of the guidelines on heart failure therapy [9].
Discussion
To the best of our knowledge, this is the first study subject-
ing a group of 15 patients with BMD (aged 11 years to 56
Contrast CMR images of patient no. 12 in the following order (from left to right): two short-axis views, a 3-chamber-view and  a 4-chamber view demonstrating a transmural pattern of LGE in the LV free wall representing myocardial damage (white  arrows) Figure 1
Contrast CMR images of patient no. 12 in the following order (from left to right): two short-axis views, a 3-chamber-view and 
a 4-chamber view demonstrating a transmural pattern of LGE in the LV free wall representing myocardial damage (white 
arrows). In addition, this patient presented with ECG changes previously described to be typical in muscular dystrophy (R:S-
ratio ≥1.0 in lead V1, a deep Q-wave in leads I, II, aVL, V5-V6 or a complete right bundle branch block).
Patient no. 12: Age = 41yrs LGE = 38.0%Journal of Cardiovascular Magnetic Resonance 2008, 10:50 http://www.jcmr-online.com/content/10/1/50
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Typical contrast CMR images of three different patients (age 26 years to 49 years) each with two short-axis and one four- chamber view Figure 2
Typical contrast CMR images of three different patients (age 26 years to 49 years) each with two short-axis and one four-
chamber view. Subepicardial LGE suggestive of myocardial damage (white arrows) was detected in all three patients in the infe-
rolateral and contiguous lateral wall with age-dependent increase in its extent (7.5% to 21.4%).
Patient no. 6: Age = 26yrs     LVEF = 65%     LGE = 7.5%
Patient no. 8: Age = 35yrs     LVEF = 40%     LGE = 17.4%
Patient no. 1: Age = 49yrs     LVEF = 41%     LGE = 21.4%Journal of Cardiovascular Magnetic Resonance 2008, 10:50 http://www.jcmr-online.com/content/10/1/50
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years) to comprehensive cardiological work-up including
LGE imaging with CMR. Our results indicate that cardiac
evaluation with CMR is more sensitive in detecting abnor-
mal findings compared to ECG and conventional echocar-
diogpraphy, respectively. The findings of this study
suggest that progressive myocardial damage is causing
regionally accentuated loss in contractility, thereby result-
ing in progressive decrease in global LV systolic function.
Furthermore, cardiac involvement in terms of myocardial
damage in patients with BMD is predominantly begin-
ning at the subepicardium of the inferolateral wall in the
3rd decade of life with age-dependent increase in its extent.
In addition, for the first time a substantial agreement
between the presence of myocardial damage (as demon-
strated by LGE imaging) and rWMA was found suggesting
that a progressive reduction in LVEF is primarily due to
the extent of myocardial damage.
Incidence of cardiac involvement in BMD
Cardiac involvement has been described in patients with
MD for decades by post-mortem analyses [15,16]. In pre-
vious studies, mainly echocardiographic and scintigraphic
methods [4,15,17] were applied for cardiac evaluation of
patients with MD: In BMD patients, cardiac involvement
was found to be uncommon in patients aged <16 years,
while more than 70% did demonstrate pathologic cardiac
findings by the age of 40 years [4,17]. Our results are in
accordance with these previous studies, since the only
three patients without any pathological finding were aged
11 years to 14 years. However, this study extends previous
knowledge, since we could demonstrate pathological
findings (including reduced LVEF and/or presence of
LGE) by CMR in all patients aged ≥23 years (n = 12;
80.0%) while conventional echocardiography revealed
pathological results only in eight patients aged ≥23 years
(53.3%; p = 0.040). The main advantage of CMR as com-
pared to conventional echocardiography is the possibility
to detect myocardial damage resulting in abnormal exam-
inations in 12 patients.
Method-based findings in BMD patients
Blood sample analysis for total CK revealed increased CK
levels in all patients included to this study. Interestingly,
higher CK-values were found in those with still preserved
LV function. This finding is in accordance with previous
studies suggesting that there is no correlation between car-
diac disease severity and the degree of skeletal myopathy
[4,17]. Surprisingly, elevated BNP levels were observed
only in two of the ten patients with depressed LV function.
One explanation for this observation may be that the
degree of LV dysfunction is not severe enough to cause a
rise in BNP [18]. Since BNP levels are supposed to also
reflect rapid changes of pressure gradients in the ventricles
[19,20], one may argue that the underlying pathophysiol-
ogy in muscular dystrophy is mainly driven by continuous
myocardial cell death (due to dystrophin absence or fra-
gility) resulting secondarily in a continuous and adapted
ventricular enlargement with progressive decrease of
systolic function without quick changes in ventricular fill-
ing pressures.
Table 3: Comparison of patients with normal and reduced LVEF as measured by CMR
All patients
n = 15
Patients with LVEF ≥ 60%
n = 5
Patients with LVEF <60%
n = 10
p value
LVEF [%] 52 (27 to 70) 65 (61 to 70) 42 (27 to 54) <0.001
Age [years] 37 (11 to 56) 14 (11 to 26) 42 (23 to 56) 0.004
BMI [kg/m2] 23 (14 to 31) 19 (14 to 23) 23 (22 to 31) 0.048
LV-EDV [ml] 182 (94 to 230) 114 (94 to 212) 192 (129 to 230) 0.047
LV-mass [g] 117 (48 to 163) 70 (48 to 155) 119 (98 to 163) 0.047
LVEDD [mm] 52 (33 to 65) 46 (33 to 57) 55 (47 to 65) 0.09
RVEF [%] 56 (42 to 66) 65 (48 to 66) 54 (42 to 59) 0.10
RV-EDV [ml] 125 (104 to 213) 116 (104 to 213) 134 (104 to 180) 0.79
GWMS 0.19 (0 to 1.06) 0 0.34 (0 to 1.06) <0.001
LGE [%] 13.0 (0 to 38.0) 0 (0 to 13.0) 17.4 (0 to 38.0) 0.010
Total CK [U/L] 1532 (310 to 28194) 3668 (2570 to 28194) 602 (310 to 3609) 0.006
Results are presented as median in addition to minimal and maximal values; LVEF = left ventricular ejection fraction; BMI = body mass index; LV-
EDV = left ventricular end-diastolic volume; LVEDD = left ventricular end-diastolic diameter; RVEF = right ventricular ejection fraction; RV-EDV = 
right ventricular end-diastolic volume; GMWS = global wall motion score; LGE = late gadolinium enhancement; CK = creatinine kinase.
Table 4: Determinants of LVEF: simple linear regression analysis 
using log [LVEF] (intercept not shown)
Variable Coefficient ± SE p value
LGE -4.67 ± 0.88 0.035
LV-EDV -0.76 ± 0.10 0.003
LV mass -0.87 ± 0.13 0.013
Age -1.43 ± 0.17 0.003
GWMS -9.44 ± 0.73 <0.001
LVEDD -0.34 ± 0.06 0.028
LVEF = left ventricular ejection fraction; LGE = late gadolinium 
enhancement; LV-EDV = left ventricular end-diastolic volume; GMWS 
= global wall motion score; LVEDD = left ventricular end-diastolic 
diameter.Journal of Cardiovascular Magnetic Resonance 2008, 10:50 http://www.jcmr-online.com/content/10/1/50
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In the past, ECG changes attracted great interest as sensi-
tive signs of cardiac involvement in BMD patients. The
typical ECG changes described in the literature were felt to
reflect a reduction in electromotive forces in the postero-
basal and contiguous lateral wall [15,21]. However, the
shortcomings of a cardiac examination relying mainly on
ECG findings are illustrated in this study: Only seven
patients (46.7%) did demonstrate some ECG abnormali-
ties with only four patients (26.7%) having those ECG
changes that were described previously to be typical in
muscular dystrophy. In comparison to ECG, 12 patients
(80.0%) had evidence of cardiac involvement by CMR
analysis.
The comparison of patients with normal and reduced
LVEF confirmed previous results: patients with reduced
LVEF were older, had larger and heavier hearts and dem-
onstrated more rWMA. Left ventricular characteristics
such as LV-EDV, LV mass and LVEDD were significantly
associated with LVEF as shown by simple linear regression
analysis. Interestingly, we found a substantial agreement
between the presence of myocardial damage as demon-
Graphs visualizing correlation analyses comprising all 15 study patients and demonstrating the association between LVEF  (measured by CMR analysis) and extent of LGE (panel A), LV-EDV (panel B), LV-mass (panel C), age (panel D), GWMS (panel  E) and LVEDD (panel F), respectively Figure 3
Graphs visualizing correlation analyses comprising all 15 study patients and demonstrating the association between LVEF 
(measured by CMR analysis) and extent of LGE (panel A), LV-EDV (panel B), LV-mass (panel C), age (panel D), GWMS (panel 
E) and LVEDD (panel F), respectively.
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strated by LGE imaging and rWMA (kappa = 0.69). Since
the highest coefficient of determination of LVEF was cal-
culated for the parameter GWMS which depends on the
extent and severity of rWMA which in turn is related to
regionally pronounced myocardial damage, we conclude
that the progressive reduction in LVEF is primarily due to
the extent of myocardial damage.
Pattern and pathophysiology of myocardial damage in 
BMD patients
In post mortem hearts, it has already been demonstrated
that myocardial damage is starting from the epicardial
third of the inferolateral wall with possible transmural
extension in contiguous segments [16,22] and a genetical
predilection of the posterobasal and lateral LV walls in
patients with MD was suggested [21]. Our results
obtained in the present study by state-of-the-art non-inva-
sive CMR imaging confirm those previous results and
impressively illustrate the tremendous progress in medi-
cine: assessment of myocardial damage which could only
be done by invasive ex vivo histopathological work-up at
necropsy in the 1960s and 1970s, is today achieved by
non-invasive in vivo CMR. Recently, Silva et al. reported
their CMR findings in a small and considerably different
collective (compared to ours) of only 10 young patients
primarily suffering from DMD. They observed myocardial
fibrosis in seven out of their 10 patients with the lateral
wall being most commonly involved [23].
The detailed cellular and molecular mechanisms leading
to myocardial contractile dysfunction in patients with MD
are still to be elucidated. Preliminary animal studies sug-
gest early alterations in cell metabolism and signal trans-
duction in dystrophin-deficient hearts with a possible
defect in the NO/cGMP pathway [24] and excessive intra-
cellular Ca-signaling and ROS generation with breakdown
of the mitochondrial membrane potential [25]. Interest-
ingly, changes in regional myocardial metabolism have
been documented at early disease stages, when rWMA or
fibrosis were still absent [21]. Therefore, morphological
changes in the myocardium of patients with MD are
believed to be a consequence of the underlying geneti-
cally-determined metabolic and structural abnormalities
which can be aggravated by additional mechanical stress.
Relevance of experiences in myocarditis for cardiac 
involvement in muscular dystrophy?
Interestingly, our group as well as other research groups
have shown previously that this subepicardial pattern of
myocardial damage which was detected predominantly in
the posterolateral myocardial wall of patients with BMD is
also a characteristic finding in biopsy-proven myocarditis
[14,26,27]. This typical feature has become useful for
non-invasive diagnosis of myocarditis by CMR (Fig. 4).
Indeed, a final common pathway leading to myocardial
damage in patients with MD and (entero-) viral myocar-
ditis has been suggested previously [28,29]. In both dis-
eases, progressive LV dysfunction is thought to be the
result of dystrophin protein disruption [30-32]. Although
cleavage of dystrophin has only been documented for cox-
sackievirus B3 [30,33], similar mechanisms for induction
of myocardial damage can be envisaged also for other car-
diotropic viruses. However, this needs further studies.
As we did not perform endomyocardial biopsies in our
patients with BMD, we could not rule out that myocarditis
was the ultimate cause of the observed posterolateral pat-
tern of myocardial damage. However, due to the fact that
almost all patients aged ≥23 years showed this pattern,
and all patients had proof of genetically determined
abnormalities of dystrophin protein, an additional infec-
tious cause seems highly unlikely.
How can one explain that a presumably diffusely distrib-
uted dystrophin abnormality in the human heart results
in a pattern of myocardial damage which is preferentially
located in the subepicardial portions of the posterolateral
wall? One possibility is that the genetically determined
dystrophin damage is not diffusely distributed but accen-
tuated in the posterolateral wall [16]. The other possibility
is that a diffuse (genetically determined) disease process
with ubiquitous alterations in cell metabolism and signal
transduction precedes functional impairment [24,25]
leading to myocardial damage preferentially in the poste-
rolateral wall. Based on this hypothesis, the myocardial
damage in the posterolateral wall could represent a non-
specific cardiac phenotype in response to exaggerated
mechanical stress in this region. The fact that a diversity of
presumably diffuse diseases such as sarcoidosis, Chagas
disease, Anderson-Fabry disease [34] or arrhythmogenic
right ventricular cardiomyopathy [35] demonstrate the
main damage in the posterolateral wall makes this yet
unproven hypothesis attractive. Different pathophysiolo-
gies (such as myocardial inflammation or intracellular
accumulation of storage products) may predispose the
human heart to myocardial damage, which is amplified
by increased mechanical stress and characterised by necro-
sis and/or fibrosis beginning in the inferolateral wall.
Whether the inferolateral wall constitutes the "weakest
cadet" of LV segments due to metabolic, structural or func-
tional characteristics or otherwise has to withstand the
highest mechanical stress during LV contraction and relax-
ation still has to be explored.
Therapeutic and prognostic consequences of CMR results
Early cardiac evaluation including state-of-the-art non-
invasive imaging of young patients with MD is required in
order to identify those who will most likely benefit from
early heart failure therapy. Timely onset of heart failure
medication has been shown to result in beneficial ven-Journal of Cardiovascular Magnetic Resonance 2008, 10:50 http://www.jcmr-online.com/content/10/1/50
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tricular remodelling with improvement in LV systolic
function or at least in retardation of progressive cardiac
dysfunction [6,7,36]. In our study group, heart disease
had already been established by echocardiographic stud-
ies in seven patients, however, only four (26.7%) were
taking heart failure medication. Obviously, the decision
about putting a patient with MD on heart failure medica-
tion cannot only be based on clinical symptoms, since
most patients suffer from skeletal myopathy and therefore
avoid exaggerated physical activity, thereby masking
potential symptoms. When considering the potential
rapid progression of cardiac involvement in these patients
and the proven beneficial effects of medical therapy
[6,7,36], extensive and regular cardiac evaluations using
LGE short-axis image of patient no. 4 (A) with a subepicardial pattern of myocardial damage in the inferolateral wall highly  resembling the myocardial damage pattern observed in patients with viral myocarditis (D) Figure 4
LGE short-axis image of patient no. 4 (A) with a subepicardial pattern of myocardial damage in the inferolateral wall highly 
resembling the myocardial damage pattern observed in patients with viral myocarditis (D). Exemplary macroscopic image of a 
different patient with muscular dystrophy (type Duchenne; B) and another different patient with chronic myocarditis (E) dem-
onstrating the similarities in the pattern of myocardial damage: note the diffuse subepicardial fibrosis along the posterolateral 
LV free walls, with almost preserved wall thickness. Corresponding full thickness histologic slides (C and F): the extensive 
fibrous tissue replacement is typically confined to the outer-mid subepicardial layer of the LV free wall.
Becker-Kiener muscular 
dystrophy (patient no. 4):
Biopsy-proven viral 
myocarditis:
Macroscopic and histologic heart image of a 
patient with muscular dystrophy:
Macroscopic and histologic heart image of a 
patient with myocarditis:
A B C
D E FJournal of Cardiovascular Magnetic Resonance 2008, 10:50 http://www.jcmr-online.com/content/10/1/50
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CMR should become the standard of cardiac care for these
patients. Recently published ACC/AHA guidelines on the
diagnosis and treatment of heart failure suggest that heart
failure therapy should be begun even in the absence of
clinical symptoms if there is evidence of structural abnor-
malities and reduced LV function [8,9]. Compared to this
standard, the majority of our patients were hitherto
undertreated. We started medical heart failure therapy in
those patients in this study who had a decreased LVEF (n
= 10; 66.7%) independent of their symptoms. Whether
patients who only show some amounts of LGE in spite of
normal LVEF – as was the case in two patients – will also
benefit from early medical therapy, has to be explored in
future studies.
Study limitations
The study size was small (with only 15 BMD patients) pre-
venting further statistical analyses. However, considering
the prevalence rate of this rare disease, it still constitutes a
substantial number and no comparable CMR-based com-
prehensive studies focusing on LGE-imaging have been
performed on a cohort of BMD patients previously,
although there is a prior case report [37]. We acknowledge
that new techniques such as CMR-based strain imaging
[38] or echocardiography-based tissue-doppler and strain
imaging [39] represent promising tools for early detection
of subclinical LV dysfunction in MD patients. However,
these techniques are still under investigation and do not
belong to the established and clinically used armentarium
of most centers. Although the value of these methods in
comparison to CMR-based LGE imaging will be of great
interest, for the purpose of this study only well accepted
and widely established echocardiographc and CMR-based
methods were applied.
Conclusion
Cardiac evaluation with CMR is more sensitive in detect-
ing abnormal findings in BMD patients compared to con-
ventional echocardiogpraphy. Myocardial damage is
predominantly beginning at the subepicardium of the
inferolateral wall – similar to cardiomyopathy in viral
myocarditis – with an age-dependent increase in its extent
and a progressive reduction of LVEF. Based on the results
of this study, regular CMR examinations in BMD patients
older than 20 years may be useful in order to prevent the
underdiagnosis of cardiac involvement and the delay in
onset of beneficial heart failure medication.
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